Condition
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Total Trials
2
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Active Not Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT04696731Phase 1Active Not RecruitingPrimary
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT06245915Phase 1Active Not RecruitingPrimary
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Showing all 2 trials